Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Binds antigen or epitope whose amino acid sequence is...
Reexamination Certificate
2005-11-29
2005-11-29
Mertz, Prema (Department: 1646)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Binds antigen or epitope whose amino acid sequence is...
C424S130100, C424S133100, C424S135100, C424S141100, C424S143100, C424S178100, C424S183100, C435S007100, C435S007200
Reexamination Certificate
active
06969519
ABSTRACT:
The present invention relates to a novel protein, TR17, which is a member of the tumor necrosis factor (TNF) receptor superfamily. In particular, isolated nucleic acid molecules are provided encoding the human TR17. TR17 polypeptides are also provided as anti TR17 antibodies and vectors, host cells and recombinant methods for producing the same. The invention further relates to methods of killing cells using the antibodies of the invention.
REFERENCES:
patent: 5969102 (1999-10-01), Bram et al.
patent: WO 98/18921 (1998-05-01), None
patent: WO 98/39361 (1998-09-01), None
patent: WO 00/40716 (2000-07-01), None
patent: WO 00/50597 (2000-08-01), None
patent: WO 00/67034 (2000-09-01), None
patent: WO 00/58362 (2000-10-01), None
Chuntharapai et al. Methods in Enzymology, vol. 288, pp. 15-27.
Skolnick et al. (2000), Nature Biotechnology, vol. 18, pp. 283-287.
Canhao et al. (2000) J. Rheumatol., 27(4):1102-1103.
Fox et al. (1997), Curr Opin Rheumatol, 9(5):393-399.
Molina et al. (1996), 60(6):699.
Von Bulow et al., NF-AT Activation Inducd by a CAML-Interacting Member of the Tumor Necrosis Factor Receptor Superfamily.(1997) Science 278:138-141.
Groom et al., Association of BAFF/BLyS overexpression and altered B cells differentiation with Sjorgen's Syndrome.J. Clin. Invest. (2002) 109:59-68.
Zhang et al., Cutting Edge: A Role for B Lymphocyte Stimulator in Systemic Lupus Erythematosus.J. Immunol. (2001) 166:6-10.
Cheema et al., Elevated Serum B Lymphocyte Stimulator Levels in Patients with Systemic Immune-Based Rheumatic Diseases,Arthritis Rheum. (2001) 44:1313-1319.
Marriette et al., A Role for B Lymphocyte Stimulator (TALL-1, BAFF, THANK,zTNF4) in Sjögren's Syndrome. 65thAnnual American College of Rheumatology Scientific Meeting. Nov. 2001.
Vaux et al., The Buzz about BAFF.J. Clin. Invest. (2002) 109:17-18.
Gross et al., TACI and BCMA are Receptors For a TNF Homologue Implicated In B-cell Autoimmune Disease.Nature(2000) 404:995-999.
Seshasyaee et al, “Loss of TACI Causes Fatal Lymphoproliferation and Autoimmunity, Establishing TACI as an Inhibitory BLyS Receptor,”Immunity, 18:279-288 (2003).
Yan et al., “Activation and accumulation of B cells in TACI-deficient mice,”Nature Immunol., 2(7):638-643 (Jul. 2001).
Waldmann, TA, “Immunotherapy: Past, Present and Future,”Nature Medicine, 9:269-277 (2003).
Moore et al., “BLyS: Member of the Tumor Necrosis Factor Family and B Lymphocyte Stimulator,”Science, 285:260-263 (1999).
Rousset et al., “Cytokine-Induced Proliferation and Immunoglobulin Production of Human B Lymphocytes Triggered through Their CD40 Antigen,”The Journal of Experimental Medicine, 173:705-710 (1991).
Baker Kevin P.
Ruben Steven M.
Human Genome Sciences Inc.
Human Genome Sciences Inc.
Mertz Prema
LandOfFree
Methods of using an agonistic antibody human tumor necrosis... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of using an agonistic antibody human tumor necrosis..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of using an agonistic antibody human tumor necrosis... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3455981